Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010100 | 0.86 | S1PR1 (0.37) | L3MBTL1HTTOPRD1TSHRS1PR1 | |
| SCHEMBL24317915 | 0.84 | L3MBTL1 (0.40) | L3MBTL1HTTSIGMAR1ALDH1A1OPRD1 | |
| SCHEMBL24317906 | 0.83 | L3MBTL1 (0.39) | L3MBTL1HTTSIGMAR1ALDH1A1PIM1 | |
| SCHEMBL9824126 | 0.81 | OPRD1 (0.33) | OPRD1S1PR1S1PR3S1PR5 | |
| SCHEMBL9824667 | 0.80 | OPRM1 (0.34) | — | |
| SCHEMBL27010104 | 0.80 | L3MBTL1 (0.38) | L3MBTL1HTTSIGMAR1ALDH1A1OPRD1 | |
| SCHEMBL8434986 | 0.79 | SIGMAR1 (0.43) | L3MBTL1HTTSIGMAR1ALDH1A1PIM1 | |
| SCHEMBL14454183 | 0.79 | L3MBTL1 (0.44) | L3MBTL1HTTSIGMAR1ALDH1A1PIM1 | |
| SCHEMBL24317917 | 0.78 | CYP1A2 (0.47) | SIGMAR1 | |
| SCHEMBL27010114 | 0.78 | L3MBTL1 (0.45) | L3MBTL1HTTSIGMAR1ALDH1A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | L3MBTL1 3664/4885HTT 19/4885SIGMAR1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.